ALXN was recommended by Blue Chip Growth at a split-adjusted $48.52 in Investment Digest issue 690, dated March 2, 2011. ALXN closed at $90.56 on Friday.
“Company leadership at Alexion Pharmaceuticals, Inc. (ALXN) has just released first-quarter operating results that have trumped estimates across the board. Compared with the same quarter last year, Alexion Pharma’s net income boomed 69% to $45.4 million. Adjusted earnings came in at $0.45 per share, which topped the $0.39 per share consensus estimate by 15%. Over the same period, net product sales jumped 47% to $244.7 million. Analysts forecast just $239.4 million in net product sales, so Alexion Pharma posted a 2% sales surprise.
“Pleased with these results, management is raising its 2012 sales guidance to between $1.065 and $1.085 billion; before, it was between $1.04 and $1.07 billion. In addition, the company is also upwardly revising its earnings guidance to a range of $1.65 and $1.75 per share. The Street currently estimates earnings of $1.74 per share on $1.07 billion in sales. ALXN, a Top 5 stock, remains a great buy for less than $98.”
- Louis Navellier, Blue Chip Growth, April 27, 2012